אילומיה
taro international ltd, israel - tildrakizumab - תמיסה להזרקה - tildrakizumab 100 mg/ml - tildrakizumab
אנהרטו
astrazeneca (israel) ltd - trastuzumab deruxtecan - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab deruxtecan 100 mg - trastuzumab
סאפנלו
astrazeneca (israel) ltd - anifrolumab - תרכיז להכנת תמיסה לאינפוזיה - anifrolumab 150 mg/ml - anifrolumab
אנטיביו תת עורי
takeda israel ltd - vedolizumab - תמיסה להזרקה - vedolizumab 158.8 mg / 1 ml - vedolizumab
נקסוויאזיים
sanofi israel ltd - avalglucosidase alpha - אבקה להכנת תמיסה מרוכזת לעירוי - avalglucosidase alpha 100 mg/vial - avalglucosidase alpha
פראלואנט 150 מגמל
sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 150 mg / 1 ml - alirocumab
פראלואנט 75 מגמל
sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 75 mg / 1 ml - alirocumab
סרדלגה
sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat
בנפיקס 250 יח' בינל
pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
בנפיקס 500 יח' בינל
pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.